Business
Press Release Jan 27 2026
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 27, 2026, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.".
About this update from Alembic Pharmaceuticals Limited
[{"type":"text","content":" Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated January 27, 2026, titled \"Alembic Pharmaceuticals Limited receives USFDA Final Approval for Difluprednate Ophthalmic Emulsion, 0.05%.\". View Attachment","length":396,"tagName":"div"}]